


Healthcare Industry News: adalimumab)
News Release - April 4, 2016
AbbVie Receives CHMP Positive Opinion for HUMIRA(R) (adalimumab) for the Treatment of Pediatric Patients, from Six Years of Age, with Moderately to Severely Active Crohn's Disease
Source: AbbVie
Issuer of this News Release is solely responsible for its
content.
Please address inquiries directly to the issuing company.
